EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

THOR: a TMB heterogeneity-adaptive optimization model predicts immunotherapy response using clonal genomic features in group-structured data

Yixuan Wang iD, Yanfang Guan, Xin Lai, Yuqian Liu, Zhili Chang, Xiaonan Wang, Quan Wang, Jingjing Liu, Jian Zhao, Shuanying Yang, Jiayin Wang, Xiaofeng Song

Briefings in Bioinformatics · 2024

DOI: 10.1093/bib/bbae648 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Briefings in Bioinformatics, 2024. Verfasst von Yixuan Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, College of Automation Engineering, Nanjing University of Aeronautics and Astronautics, 29 Jiangjun Avenue, Jian…. Hauptthemen laut MEDLINE: Immunotherapy, Neoplasms, Mutation, Biomarkers, Tumor. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Postdoctoral Fellowship Program of CPSF.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

With the increasing number of indications for immune checkpoint inhibitors in early and advanced cancers, the prospect of a tumor-agnostic biomarker to prioritize patients is compelling. Tumor mutation burden (TMB) is a widely endorsed biomarker that quantifies nonsynonymous mutations within tumor DNA, essential for neoantigen production, which, in turn, correlates with the immune response and guides decision-making. However, the general clinical application of TMB—relying on simple mutational counts targeted at a single endpoint—does not adequately capture the complex clonal structure of tumors nor the multifaceted nature of prognostic indicators. This recognition has spurred the exploration of sophisticated high-dimensional regression techniques. Unfortunately, the limited cohort sizes in immunotherapy trials have hindered the full potential of these advanced methods. Our approach considers patient subgroups as related yet distinct entities, enabling precise tailoring and refinement to address subgroup-specific dynamics. Given the deficiencies and the constraints, we introduce a TMB heterogeneity-optimized regression (THOR). This innovative model enhances the predictive capabilities of TMB by integrating tumor clonality and a diverse spectrum of clinical endpoints, further augmented by fusion techniques across subgroups to facilitate robust data sharing and interpretation. Our simulations validate THOR’s superiority in parameter estimation for statistical inference. Clinically, we assess the utility of THOR in a structured cohort of 238 cancer patients undergoing immunotherapy, supplemented by 2212 patients across 19 subgroups from public datasets. The forecast of the responses and comparison of survival hazards demonstrate that THOR significantly enhances patient stratification and prognostic predictions by incorporating complex immunogenetic biology and subgroup-specific dynamics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyNeoplasmsMutationBiomarkers, TumorHumansGenomicsPrognosis

Stichwörter der Autor:innen

cancer immunotherapyendpoint integrationgroup-structured datapenalized fusion strategyprognostic biomarkertumor clonal heterogeneity

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Biomedical Engineering, College of Automation Engineering, Nanjing University of Aeronautics and Astronautics, 29 Jiangjun Avenue, Jiangning, Nanjing 211106, China.
  • School of Computer Science and Technology, Faculty of Electronics and Information Engineering, Xi'an Jiaotong University, 28 Xianning West Road, Beilin, Xi'an 710049, China.
  • Geneplus-Beijing Institute, 8 Life Park Road, Changping, Beijing 102206, China.
  • Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., 128 Huakang Road, Pukou, Nanjing 210032, China.
  • Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, 3 Shangqin Road, Xincheng, Xi'an 710004, China.

ORCID-Profile: Yixuan Wang

Förderung

  • National Natural Science Foundation of China
  • Postdoctoral Fellowship Program of CPSF

Zitieren

APA

Wang, Y., Guan, Y., Lai, X., Liu, Y., Chang, Z., Wang, X., Wang, Q., Liu, J., Zhao, J., Yang, S., Wang, J., & Song, X. (2024). THOR: a TMB heterogeneity-adaptive optimization model predicts immunotherapy response using clonal genomic features in group-structured data. Briefings in Bioinformatics. https://doi.org/10.1093/bib/bbae648

Vancouver

Wang Y, Guan Y, Lai X, Liu Y, Chang Z, Wang X, et al. THOR: a TMB heterogeneity-adaptive optimization model predicts immunotherapy response using clonal genomic features in group-structured data. Briefings in Bioinformatics. 2024. doi:10.1093/bib/bbae648

BibTeX
@article{Wang2024,
  author = {Wang, Yixuan and Guan, Yanfang and Lai, Xin and Liu, Yuqian and Chang, Zhili and Wang, Xiaonan and Wang, Quan and Liu, Jingjing and Zhao, Jian and Yang, Shuanying and Wang, Jiayin and Song, Xiaofeng},
  title = {THOR: a TMB heterogeneity-adaptive optimization model predicts immunotherapy response using clonal genomic features in group-structured data},
  journal = {Briefings in Bioinformatics},
  year = {2024},
  doi = {10.1093/bib/bbae648}
}
Kostenlos starten →